Orthotopic liver transplantation in combination with neoadjuvant therapy: A new paradigm in the treatment of unresectable intrahepatic cholangiocarcinoma

Current Opinion in Gastroenterology

Volumn 28, Issue 3, 2012, Pages 258-265

  Rana, Abbas ^a   Hong, Johnny C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

hepatic resection; intrahepatic cholangiocarcinoma; neoadjuvant chemoradiation therapy; orthotopic liver transplantation; predictive index; tumor recurrence free survival

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; CAPECITABINE; CYTOKINE; FLUOROURACIL; REACTIVE OXYGEN METABOLITE;

ADJUVANT CHEMOTHERAPY; BILE DUCT CARCINOMA; CANCER INVASION; CHEMOEMBOLIZATION; CHOLANGITIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISTANT METASTASIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTRAHEPATIC CHOLANGIOCARCINOMA; JAUNDICE; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL HEPATECTOMY; PATIENT SELECTION; PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY; PREOPERATIVE EVALUATION; PRURITUS; RADIATION DOSE; RADICAL RESECTION; RECURRENCE FREE SURVIVAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOADJUVANT THERAPY; PATIENT SELECTION; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84859918917     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32835168db     Document Type: Review

References (69)

1. Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma. Arch Surg 2011; 146:683-689.
2. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24:115-125. (Pubitemid 38738341)
3. Sempoux C, Jibara G, Ward SC, et al. Intrahepatic cholangiocarcinoma. New insights in pathology. Semin Liver Dis 2011; 31:49-60.
4. Lang H, Sotiropoulos GC, Sgourakis G, et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009; 208:218-228.
5. Jonas S, Thelen A, Benckert C, et al. Extended liver resections for intrahepatic cholangiocarcinoma: a comparison of the prognostic accuracy of the fifth and sixth editions of the TNM classification. Ann Surg 2009; 249:303-309.
6. Taylor-Robinson SD, Foster GR, Arora S, et al. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350:1142-1143. (Pubitemid 27454010)
7. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33:1353-1357. (Pubitemid 32496970)
8. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69:1633-1637.
9. Ghali P, Marotta PJ, Yoshida EM, et al. Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl 2005; 11:1412-1416. (Pubitemid 43071591)
10. Robles R, Figueras J, Turrion VS, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 2004; 239:265-271. (Pubitemid 38176362)
11. De Vreede I, Steers JL, Burch PA, et al. Prolonged disease free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000; 6:309-316. (Pubitemid 30317226)
12. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003; 37:961-969. (Pubitemid 36538671)
13. Lazaridis K, Gores G. Cholangiocarincoma. Gastroenterology 2005; 128:1655-1667.
14. Bergquist A, Broome U. Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001; 15:643-656. (Pubitemid 32747016)
15. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36:321-327. (Pubitemid 34194790)
16. Tanaka M, Tanka H, Tsukuma H. Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepat 2010; 17:742-748.
17. Petrowsky H, Hong J. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Trans Proceedings 2009; 41:4023-4035.
18. Poultsides GA, Zhu AX, Choti MA, et al. Intrahepatic cholangiocarcinoma. Surg Clin North Am 2010; 90:817-837.
19. Patel T. Cholangiocarcinoma: controversies and challenges. Nat Rev Gastroenterol Hepatol 2011; 8:189-200.
20. Patel AH, Harnois DM, KleeGG, et al. The utility of CA 19-9 in the diagnosis of cholangiocarincoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95:204-207. (Pubitemid 30041560)
21. Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998; 58:512-518. (Pubitemid 28087416)
22. Vestergaard EM, Hein HO, Meyer H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999; 45:54-61. (Pubitemid 29036385)
23. Gatto M, Bragazzi MC, Semeraro R, et al. Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 2010; 42:253-260.
24. Petrowsky H, Wildbrett P, Husarik DB, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006; 45:43-50 (Pubitemid 43850623)
25. Kim JY, Kim MH, Lee TY, et al. Clinical role of 18F-FD PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008; 103:1145-1151. (Pubitemid 351677961)
26. Raman SS, Lu DS, Chen SC, et al. Hepatic MR imaging using ferumoxides: prospective evaluation with surgical and intraoperative sonographic confirmation in 25 cases. AJR Am J Roentgenol 2001; 177:807-812. (Pubitemid 32881654)
27. Kornberg A, Freesmeyer M, Barthel E, et al. 18F-FDG uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009; 9:592-600.
28. Baron TH, Harewood GC, Rumalla A, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004; 2:214-219. (Pubitemid 38293308)
29. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004; 99:1675-1681. (Pubitemid 39237490)
30. Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248:84-96.
31. Weimann A, Varnholt H, Schlitt HJ, et al. Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg 2000; 87:1182-1187.
32. Jan YY, Yeh CN, Yeh TS, et al. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol 2005; 11:1779-1784.
33. Paik KY, Jung JC, Heo JS, et al. What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol 2008 23 766-770. (Pubitemid 351519418)
34. Tamandl D, Herberger B, Gruenberger B, et al. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008; 15:2787-2794.
35. Zhou XD, Tang ZY, Fan J, et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2009; 135:1073-1080.
36. Weber SM, Jarnagin WR, Klimstra D, et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001; 193:384-391. (Pubitemid 32895979)
37. Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356:1545-1559. (Pubitemid 46588419)
38. Makuuchi M, Thai BL, Takayasu K, et al. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 1990; 107:521-527. (Pubitemid 20156653)
39. Nagino M, Kamiya J, Kanai M, et al. Right trisegment portal vein embolization for biliary tract carcinoma: technique and clinical utility. Surgery 2000; 127:155-160. (Pubitemid 30091261)
40. Kishi Y, Madoff DC, Abdalla EK, et al. Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery 2008 144 744-751.
41. Stieber AC, Marino IR, Iwatsuki S, et al. Cholangiocarcinoma in sclerosing cholangitis. The role of liver transplantation. Int Surg 1989; 74:1-3. (Pubitemid 19135307)
42. Goldstein RM, Stone M, Tillery GW, et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 1993 166 768-771.
43. Brandsaeter B, Isoniemi H, Broome U, et al. Liver transplantation for primary sclerosing cholangitis: predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40:815-822. (Pubitemid 38507363)
44. Becker NS, Rodriquez JA, Barshes NR, et al. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008; 12:117-122.
45. Stieber AC, Marino IR, Iwatsuki S, Starzl TE. Cholangiocarcinoma in sclerosing cholangitis: the role of liver transplantation. Int Surg 1989; 74:1-3. (Pubitemid 19135307)
46. Shimoda M, Farmer DG, Colquhoun SD, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 2001; 7:1023-1033. (Pubitemid 34023989)
47. Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002; 2:774-779. (Pubitemid 36342621)
48. Robles R, Figueras J, Turrion VS, et al. Liver transplantation for peripheral cholangiocarcinoma: Spanish experience. Transplant Proc 2003; 35:1823-1824. (Pubitemid 37093725)
49. Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 2006; 82:1703-1707. (Pubitemid 46035655)
50. Morris-Stiff G, Bhati C, Olliff S, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig Surg 2008; 25:126-132. (Pubitemid 351748768)
51. Sotiropoulos GC, Kaiser GM, Lang H, et al. Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience. Transplant Proc 2008; 40:3194-3195.
52. Goss JA, Shackleton CR, Farmer DG, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997; 225:472-481.
53. Hong JC, Petrowsky H, Kaldas FM, et al. Predictive Index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. J Am Coll Surg 2011; 212:514-520.
54. Carrafiello G, Lagana D, Cotta E, et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol 2010; 33:835-839.
55. Gusani NJ, Balaa FK, Steel JL. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 2008; 12:129-137.
56. Kiefer MV, Albert M, McNally M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011; 117:1498-1505.
57. Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26:657-664. (Pubitemid 351264363)
58. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multiinstitutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009; 27:1572-1578.
59. Kopek N, Holt MI, Hansen AT, et al. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010; 94:47-52.
60. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362:1273-1281.
61. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593-600. (Pubitemid 26285639)
62. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008; 13:415-423. (Pubitemid 351679921)
63. Mazhar D, Stebbing J, Bower M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol 2006 2 509-514 (Pubitemid 44304609)
64. Okada T, Sawada T, Kubota K. Rapamycin inhibits growth of cholangiocarcinoma cells. Hepatogastroenterology 2009; 56:6-10.
65. Toso C, Merani S, Bigam DL, et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51:1237-1243.
66. Zimmerman MA, Trotter JF, Wachs M, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14:633-638. (Pubitemid 351696274)
67. Panjala C, Senecal DL, Bridges MD, et al. The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. Am J Transplant 2010; 10:1263-1267.
68. Sapisochin G, Fidelman N, Roberts JP, et al. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl 2011; 17:934-942.
69. Maganty K, Levi D, Moon J, et al. Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation. Dig Dis Sci 2010; 55:3597-3601.